Information Provided By: 
Fly News Breaks for June 10, 2019
NTRA
Jun 10, 2019 | 05:55 EDT
Piper Jaffray analyst William Quirk raised his price target for Natera to $28 from $23 and traveling with management and reiterates an Overweight rating on the shares. Natera is on the cusp of a multi year revenue acceleration cycle, Quirk tells investors in a research note. He believes Signatera in colorectal cancer can potentially contribute sooner than expected and highlights the American College of Obstetricians and Gynecologists endorsing average risk NIPT.
News For NTRA From the Last 2 Days
There are no results for your query NTRA
